Navigation Links
Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimer's Disease From Merck
Date:12/21/2011

Previously, Dr. Hefti was Senior Vice President of Neuroscience Research at Merck, Director of Neuroscience Research at Genentech, and a Professor at the University of Southern California and Associate Professor at the University of Miami.

"The recent failures of a gamma secretase inhibitor and the limited efficacy observed so far with non-selective amyloid beta immunotherapies indicates that industry may have been focused on suboptimal targets within the amyloid beta pathways," stated Dr. Hefti. "Our Merck colleagues successfully advanced anti-ADDL antibody therapeutics to a late pre-clinical development stage based on antibodies that we believe will allow Acumen to develop a best in class, disease modifying therapy for Alzheimer's disease."

William Goure, Ph.D., has been appointed Acumen's Chief Operating Officer, a position he formerly held.

About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a development stage biotechnology company focused on discovering and developing best in class therapeutics and diagnostics for Alzheimer's disease. Acumen owns or has exclusive license rights to key patents, related intellectual property and drug development capabilities relating to amyloid beta soluble oligomers, now widely believed to be an underlying cause of Alzheimer's disease. Acumen is partnered with Merz Pharmaceuticals, GmbH for the development of certain small molecule therapeutics for Alzheimer's disease.


'/>"/>
SOURCE Acumen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
2. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
7. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
8. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
9. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
11. Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... clinical grade hypothermic storage and cryopreservation freeze ... cells and tissues  ("BioLife" or the "Company"), today announced that ... May 4, 2015 (the "Annual Meeting"). Because the ...
(Date:12/24/2014)... Earlier this year in a June 24 international conference ... Cell Technology Center, LLC ( ASCTC ) focused attention on ... tissue stem cells. His title “Asymmetric Self-Renewal by Distributed ... embodied the essence of his message to congress participants. ...
(Date:12/24/2014)... York (PRWEB) December 23, 2014 According to ... Long Island Affiliate of ITRA Global, the national office market ... steady recovery. This is evidenced by the third quarter’s ... stock market. Low energy costs have held inflation down ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... May 26, 2011 PAREXEL International Corporation (NASDAQ: ... today announced that it has been selected as one ... clinical development services. PAREXEL will work with ... its clinical development programs while delivering a high level ...
... NEW YORK, May 26, 2011 ... market research report is available ... Technology Transfer Strategies - ... Within the Pharmaceutical and Biopharmaceutical ...
... what differentiates cancer cells from normal cells is limited by ... of individual cells. By combing two different methods, a team ... a tool for studying signal paths on several levels at ... PLoS One . "We also show that the ...
Cached Biology Technology:Pfizer Inc. and PAREXEL International Corp. Sign Strategic Partnership Agreement to Advance Clinical Development 2Pfizer Inc. and PAREXEL International Corp. Sign Strategic Partnership Agreement to Advance Clinical Development 3Pfizer Inc. and PAREXEL International Corp. Sign Strategic Partnership Agreement to Advance Clinical Development 4Pfizer Inc. and PAREXEL International Corp. Sign Strategic Partnership Agreement to Advance Clinical Development 5Reportlinker Adds Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries 2Reportlinker Adds Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries 3Reportlinker Adds Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries 4Reportlinker Adds Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries 5Reportlinker Adds Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries 6Reportlinker Adds Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries 7Reportlinker Adds Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries 8Reportlinker Adds Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries 9Combo method reveals cells' signal systems 2
(Date:12/22/2014)... (NASDAQ: NXTD and NXTDW) ("NXT-ID" or the ... commerce market, announces it has retained famous pickpocket, entertainer and ... CES debut of the Wocket™ biometric smart wallet.  ... booth January 6th and 7 th , 2015, demonstrating some ...
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., the ... study that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four hundred years ... as a meeting place for peoples from different continents. This ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... has proposed a set of basic rules to help ... Their proposal is being unveiled at the World ... six regional governments plus Australia and the United States ... world history, the Coral Triangle Initiative. "The catastrophic ...
... personnel from the U.S. Armed Forces, as well as ... other first-responder personnel from throughout the United States, and ... the 2009 Force Protection Equipment Demonstration (FPED VII). The ... Marine Corps Base, Quantico, VA, during May 19-21.The demonstration, ...
... Casey Weaver, University of Alabama at Birmingham professor of ... Outstanding Innovation in Life Sciences. The prize, which ... advancing understanding of immune protection and immune disease through ... bodies use T cells to protect against infections and ...
Cached Biology News:Rules proposed to save the world's coral reefs 2Rules proposed to save the world's coral reefs 3Demonstration Features Commercial Technology for Combating Terrorism 2UAB professor receives HudsonAlpha Innovation Prize 2
... Probes EnzChek Pyrophosphate Detection Kit,provides a ... measuring the inorganic pyrophosphate (PPi ) ... such as DNA and,RNA polymerizations, cyclic ... and the enzymatic activation of fatty ...
... deoxynucleotidyl transferase (TdT) is an intracellular marker ... thymocytes and minor subpopulation of bone marrow ... increased numbers of TdT cells are found ... and lymphomas. Presence of TdT thus provides ...
... FREEZE. Nuclear matrix proteins (NMPs) make up the ... associated with such functions as DNA replication, RNA ... matrix has been shown to be highly insoluble ... that cell death releases soluble nuclear matrix proteins ...
Recombinant Cat Interferon Alpha Activity: 2.7 x 10 7 u/mg...
Biology Products: